Literature DB >> 9882305

A replication-incompetent adenovirus vector with the preterminal protein gene deleted efficiently transduces mouse ears.

J W Moorhead1, G H Clayton, R L Smith, J Schaack.   

Abstract

Adenoviruses offer great potential as gene therapy agents but are limited by the strong inflammatory response that occurs in response to the recombinant virus. Since the degree of inflammation correlates in part with the potential of the viral vector for replication, we constructed a preterminal protein (pTP) deletion mutant adenovirus type 5 vector, Ad5dl308DeltapTPbeta-gal, that is replication incompetent due to deletion of the pTP gene and that has the E1 genes replaced by the Escherichia coli lacZ reporter gene under the control of the cytomegalovirus major immediate-early promoter. This virus was compared with a first-generation, replication-defective adenovirus vector, Ad5dl308beta-gal, that is isogenic except that it contains a wild-type pTP gene. To examine transduction efficiency and induction of inflammation, we developed a novel system involving intradermal injection of BALB/c mouse ears. Mouse ears can be accurately measured to determine the degree of edema as an indirect measurement of inflammation. Edema and inflammation were induced in a dose- and time-dependent manner by both viruses and correlated well. LacZ activity correlated inversely with edema and inflammation. The pTP-defective vector Ad5dl308DeltapTPbeta-gal transduced mouse ears much more efficiently and induced edema and inflammatory cell infiltration approximately 10-fold less efficiently than the first-generation vector Ad5dl308beta-gal. The diminished inflammatory response and increased efficiency of transduction observed with Ad5dl308DeltapTPbeta-gal indicate its promise as a gene therapy agent for other tissues. The results also demonstrate that the mouse ear model offers potential for the study of adenovirus-induced inflammation because of the ready access of the ears, the relative ease of continuous measurement, and the sensitivity to adenovirus transducing vectors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9882305      PMCID: PMC103924     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4.

Authors:  D E Brough; A Lizonova; C Hsu; V A Kulesa; I Kovesdi
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

2.  Safety and efficacy of in vivo gene transfer into the porcine heart with replication-deficient, recombinant adenovirus vectors.

Authors:  J Mühlhauser; M Jones; I Yamada; C Cirielli; P Lemarchand; T R Gloe; B Bewig; S Signoretti; R G Crystal; M C Capogrossi
Journal:  Gene Ther       Date:  1996-02       Impact factor: 5.250

3.  Nondepleting anti-CD4 antibody treatment prolongs lung-directed E1-deleted adenovirus-mediated gene expression in rats.

Authors:  D Lei; M Lehmann; J E Shellito; S Nelson; A Siegling; H D Volk; J K Kolls
Journal:  Hum Gene Ther       Date:  1996-12-01       Impact factor: 5.695

4.  Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5.

Authors:  J M Bergelson; J A Cunningham; G Droguett; E A Kurt-Jones; A Krithivas; J S Hong; M S Horwitz; R L Crowell; R W Finberg
Journal:  Science       Date:  1997-02-28       Impact factor: 47.728

5.  Adenovirus-mediated gene transfer to rat testis in vivo.

Authors:  K T Blanchard; K Boekelheide
Journal:  Biol Reprod       Date:  1997-02       Impact factor: 4.285

6.  Immediate inflammatory responses to adenovirus-mediated gene transfer in rat salivary glands.

Authors:  M R Adesanya; R S Redman; B J Baum; B C O'Connell
Journal:  Hum Gene Ther       Date:  1996-06-10       Impact factor: 5.695

7.  Characterization of a replication-incompetent adenovirus type 5 mutant deleted for the preterminal protein gene.

Authors:  J Schaack; X Guo; S J Langer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

8.  Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy.

Authors:  G P Gao; Y Yang; J M Wilson
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

9.  Restricted replication of human adenovirus type 5 in mouse cell lines.

Authors:  G E Blair; S C Dixon; S A Griffiths; M E Zajdel
Journal:  Virus Res       Date:  1989-12       Impact factor: 3.303

10.  Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors.

Authors:  F J Fallaux; O Kranenburg; S J Cramer; A Houweling; H Van Ormondt; R C Hoeben; A J Van Der Eb
Journal:  Hum Gene Ther       Date:  1996-01-20       Impact factor: 5.695

View more
  9 in total

1.  E1A and E1B proteins inhibit inflammation induced by adenovirus.

Authors:  Jerome Schaack; Michael L Bennett; Jeff D Colbert; Andres Vazquez Torres; Gerald H Clayton; David Ornelles; John Moorhead
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-19       Impact factor: 11.205

Review 2.  Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Authors:  Seung T Lim; Mikko Airavaara; Brandon K Harvey
Journal:  Pharmacol Res       Date:  2009-10-17       Impact factor: 7.658

Review 3.  Emerging Gene Therapies for Genetic Hearing Loss.

Authors:  Hena Ahmed; Olga Shubina-Oleinik; Jeffrey R Holt
Journal:  J Assoc Res Otolaryngol       Date:  2017-08-16

4.  Strong foreign promoters contribute to innate inflammatory responses induced by adenovirus transducing vectors.

Authors:  Jerome Schaack; Michael L Bennett; Gary S Shapiro; James DeGregori; James L McManaman; John W Moorhead
Journal:  Virology       Date:  2011-01-20       Impact factor: 3.616

5.  An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors.

Authors:  Daniele Catalucci; Elisabetta Sporeno; Agostino Cirillo; Gennaro Ciliberto; Alfredo Nicosia; Stefano Colloca
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Transduction of the mammary epithelium with adenovirus vectors in vivo.

Authors:  Tanya D Russell; Andreas Fischer; Neal E Beeman; Emily F Freed; Margaret C Neville; Jerome Schaack
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

7.  Construction and preliminary characterization of a library of "lethal" preterminal protein mutant adenoviruses.

Authors:  J Schaack; W Y Ho; S Tolman; E Ullyat; X Guo; N Frank; P I Freimuth; D J Roovers; J S Sussenbach
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

Review 8.  Conditionally replicating adenoviruses for cancer treatment.

Authors:  Youssef Jounaidi; Joshua C Doloff; David J Waxman
Journal:  Curr Cancer Drug Targets       Date:  2007-05       Impact factor: 3.428

Review 9.  Delivery systems for pulmonary gene therapy.

Authors:  Ajay Gautam; Clifford J Waldrep; Charles L Densmore
Journal:  Am J Respir Med       Date:  2002
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.